Omidenepag is a selective, non-prostanoid EP2 receptor agonist used to treat glaucoma and ocular hypertension by effectively reducing intraocular pressure. This category provides essential reference standards,… Read more
Omidenepag is a selective, non-prostanoid EP2 receptor agonist used to treat glaucoma and ocular hypertension by effectively reducing intraocular pressure. This category provides essential reference standards, including the active pharmaceutical ingredient, its prodrug form Omidenepag Isopropyl, and related degradation products such as N-nitroso impurities. These high-quality compounds are critical for laboratory personnel performing impurity profiling, method development, and validation in pharmaceutical quality control. By utilizing these precise analytical standards, laboratories can ensure the accurate identification and quantification of potential process-related impurities and degradation markers. These materials support rigorous testing protocols necessary for maintaining regulatory compliance and ensuring the purity and stability of pharmaceutical formulations containing this therapeutic agent.